Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route

Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates

Peralta-Álvarez MP. et al, (2024), npj Vaccines, 9

Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans

Voogd L. et al, (2024), Vaccines, 12, 1129 - 1129

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668

Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.

Audran R. et al, (2024), J Infect

Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.

Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148

Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.

Balasingam S. et al, (2024), The Journal of infectious diseases

Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.

Ma J. et al, (2024), Proceedings of the National Academy of Sciences of the United States of America, 121

Revaccination with BCG: does it work?

McShane H., (2024), The Lancet. Infectious diseases

Improving TB vaccine trial efficiency: A tough nut to crack.

Mcshane H., (2023), The Journal of infectious diseases

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.

Morrison H. et al, (2023), Frontiers in immunology, 14

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi.

Gordon SB. et al, (2023), Wellcome Open Res, 8

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants

Satti I. et al, (2022), Nature Communications, 13

Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.

Williams E. et al, (2022), Vaccine, 40, 3484 - 3489

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.

Wilkie M. et al, (2022), Scientific reports, 12

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?

Dockrell HM. and McShane H., (2022), EBioMedicine, 79

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Killingley B. et al, (2022), Nat Med

Challenges in Developing a Controlled Human Tuberculosis Challenge Model.

Jackson S. and McShane H., (2022), Curr Top Microbiol Immunol

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Fisher BA. et al, (2022), The Lancet Respiratory Medicine, 10, 255 - 266

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?